BNP Paribas Financial Markets
UNCY icon

BNP Paribas Financial Markets’s Unicycive Therapeutics UNCY Stock Holding History

BNP Paribas Financial Markets’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$787K Buy
119,531
+19,789
+20% +$130K ﹤0.01% 3300
2025
Q4 		$576K Buy
99,742
+99,687
+181,249% +$532K ﹤0.01% 3491
2025
Q3 		$240 Buy
+55
New +$240 ﹤0.01% 5372

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BNP Paribas Financial Markets's UNCY Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Unicycive Therapeutics (UNCY) stake by 20% in Q1 2026, buying an estimated $130K and bringing the position to 119,531 shares worth $787K. The position accounts for ﹤0.01% of the portfolio, ranked #3300.

BNP Paribas Financial Markets first reported a position in UNCY in Q3 2025 and has held it in 3 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • BNP Paribas Financial Markets held 119,531 shares of Unicycive Therapeutics worth $787K as of Q1 2026.
  • BNP Paribas Financial Markets bought 19,789 Unicycive Therapeutics shares in Q1 2026, an estimated $130K.
  • Unicycive Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3300 holding.
  • BNP Paribas Financial Markets first reported a position in Unicycive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.